cloprostenol and dinoprost-tromethamine

Due to the limited literature available evaluating doses of Prostaglandin F2α in donkeys, doses for horses have been extrapolated and used as guidelines. This study aimed to assess the efficacy and side effects of four different cloprostenol sodium and dinoprost tromethamine doses to induce luteolysis in jennies. Sixty-three cycles of seven Jennies (nine cycles per jenny) were used in this study. Seven days after ovulation, jennies randomly received one of the treatments in a crossover design as follows: Control, no treatment was administered; C1, 250 µg of cloprostenol sodium (CS, Estrumate , Merck Animal Health, USA); C2, 125 µg of CS; C3, 65.5 µg of CS, C4, 37.5 µg of CS; DT1, 5 mg of dinoprost tromethamine (DT, Lutalyse, Zoetis, USA); DT2, 2.5 mg of DT; DT3, 1.25 mg of DT; DT4, 0.625 mg of DT. Jennies were monitored for 30 minutes following treatment, and adverse effects were recorded. The measurement of the corpus luteum (CL) and the length of the estrous cycle were recorded. All DT and CS treatment doses were effective (P < .0001) in reducing the estrous cycle length compared to jenny's Control cycle. The CL volume was decreased in all treated groups one day after treatment (P < .05). The adverse effects were reduced as the dose of both Prostaglandin F2α analogs were reduced. In conclusion, a single low dose of dinoprost tromethamine (0.625 mg) or cloprostenol sodium (37.5 µg) can induce luteolysis and shorten the estrous length in jennies producing fewer adverse effects.

Topics: Animals; Cloprostenol; Dinoprost; Equidae; Female; Horses; Luteolysis; Progesterone

Using two PGF(2α) treatments 14 days apart as a way to enhance estrus detection rate following the 2nd treatment is a reproductive management tool that continues to be used on large dairy farms. In one study, in cows with a functional CL and a dominant follicle, treatment with cloprostenol vs. dinoprost resulted in greater peripheral estradiol concentrations. The objective of the present study was to determine if cloprostenol could enhance pregnancy rates of cows in a large dairy herd using a PGF(2α) program for 1st artificial insemination (AI). Lactating dairy cows (n = 4549) were randomly assigned to receive two treatments of either 500 μg cloprostenol or 25 mg dinoprost 14 days apart, with the 2nd treatment on the 1st day of the voluntary waiting period (57 DIM). Cows detected in estrus within 5 days after the 2nd treatment were inseminated. There was no effect of treatment on day of estrus detection, with 78% of cows inseminated on Days 3 or 4 following treatment. Cloprostenol increased (P < 0.01) estrus detection rates in 1st parity cows compared to dinoprost, 42.4 vs. 34.0%. In cows inseminated on Days 3 or 4 after treatment, cloprostenol increased (P = 0.05) conception rates compared to dinoprost, 38.3 vs. 34.4%. When treatments and parities were combined, conception rates increased (P < 0.02) with interval after treatment (27.0, 36.4, and 44.5% for Days 1 or 2, Days 3 or 4, and Day 5, respectively). Cloprostenol increased (P = 0.02) overall pregnancy rate compared to dinoprost, 14.4 vs. 12.2%. In summary, cloprostenol increased fertility in 1st parity cows inseminated on Days 3 or 4 following treatment and subsequently enhanced pregnancy rates of 1st parity lactating dairy cows compared to dinoprost. Fertility appeared greater in cows expected to have had a young antral ovarian follicle at treatment.

Topics: Animals; Cattle; Cloprostenol; Commerce; Dairying; Dinoprost; Estrus Detection; Female; Fertilization; Lactation; Luteolytic Agents; Pregnancy; Pregnancy Rate; Pregnancy, Animal; Up-Regulation

The probability of a pregnancy decreases substantially in lactating dairy cows treated with Ovsynch if luteolysis is delayed or incomplete. Two PGF(2α) products are currently approved in the United States for luteolysis in lactating dairy cattle, dinoprost tromethamine and cloprostenol sodium. Cloprostenol has a longer half-life compared with dinoprost, is more resistant to endogenous metabolism, and is maintained in circulation longer. We hypothesized that cloprostenol could reduce the time to complete luteolysis compared with dinoprost because of differences in half-life. Lactating dairy cows received the same presynchronization strategy (G6G; 25mg of PGF(2α) - 2 d - 100 μg of GnRH - 6 d - 100 μg of GnRH - 7 d - final PGF(2α) treatment). At the time of the final PGF(2α), cows (n=35) were randomly assigned to receive either 500μg of cloprostenol or 25mg of dinoprost. Blood samples were collected daily before and serially after PGF(2α) treatment to analyze circulating concentrations of progesterone (P(4)) and estradiol (E(2)). Ultrasound examinations of ovaries were performed to measure sizes of follicles and corpora lutea (CL) and determine time of ovulation. Considering only cows with complete luteolysis, mean circulating P(4) was lower for cows given cloprostenol than for those given dinoprost between 0 and 12h postinjection, but not at 24, 36, or 48 h. A rapid decrease in P(4) was observed 1h after PGF(2α) (6.54 ± 0.27 to 3.77 ± 0.22 ng/mL) followed by a complete rebound 1h later (3.77 ± 0.22 to 5.07 ± 0.31 ng/mL) followed by a steady decline in both treatment groups. Serum concentrations of E(2) were greater at 48 h posttreatment in cloprostenol-treated cows (2.74 ± 0.15 pg/mL) than in dinoprost-treated cows (2.37 ± 0.19 pg/mL). Cows that did not have complete luteolysis did not ovulate (0/7) during the 6-d period following treatment. Time to complete luteolysis and ovulation was 29.1 ± 1.1 versus 29.4 ± 1.7 and 101 versus 103 h posttreatment in cloprostenol compared with dinoprost. A negative relationship was observed between P(4) at 12h posttreatment and concentrations of E(2) 48 h posttreatment (b=-0.6905; R(2)=0.23). In summary, cows treated with cloprostenol had lower concentrations of P(4) for the first 12h following treatment and subsequently greater concentrations of E(2) compared with dinoprost, although no differences were observed in these 2 PGF(2α) analogs for time to complete luteolysis or time to ovulation.

Topics: Animals; Cattle; Cloprostenol; Dinoprost; Estradiol; Estrus Synchronization; Female; Lactation; Luteolysis; Luteolytic Agents; Pregnancy; Progesterone; Time Factors; Treatment Outcome

Luteolysis is a key event in Ovsynch programs of lactating dairy cows. Studies indicate that as many as 20% of cows treated with a Presynch/Ovsynch program have delayed or incomplete luteolysis using dinoprost tromethamine. Cows must have complete luteolysis to have a chance to become pregnant. Dinoprost tromethamine has a short half-life of approximately 7 to 8min. Cloprostenol sodium is more resistant to endogenous metabolism and is maintained in circulation for a longer time (half-life=3h). The objective was to determine if cloprostenol sodium could increase the percentage of cows with complete luteolysis and subsequent pregnancy per artificial insemination (P/AI) in lactating dairy cows compared with dinoprost tromethamine when administered within a presynchronization plus Ovsynch program for first artificial insemination (n=652) and an Ovsynch resynchronization program for second or later AI (second+; n=394). Blood samples were collected daily for 5 d beginning at the PGF(2α) of Ovsynch in a subset of cows (n=680) for first and second+ AI to measure circulating concentrations of progesterone (P(4)) and estradiol (E(2)). Complete luteolysis was defined as cows with functional corpus luteum (CL) at time of treatment and serum concentrations of P(4) <0.5 ng/mL at 56, 72, and 96 h after treatment. Percentage of cows with functional CL that had complete luteolysis after treatment was not greater for cloprostenol sodium compared with dinoprost tromethamine in first (79 vs. 80%, respectively) or second+ AI (70 vs. 72%, respectively). In addition, mean serum concentrations of P(4) were not less for cows treated with cloprostenol sodium following treatment. Pregnancy per AI of cows treated with cloprostenol sodium tended to be greater than dinoprost tromethamine for first (40 vs. 35%; respectively) but not second+ AI (23 vs. 21%, respectively). Cows with greater serum P(4) concentrations at time of PGF(2α) of Ovsynch had a greater probability of undergoing complete luteolysis after PGF(2α) of Ovsynch and pregnancy at 39 d after timed AI (i.e., 50% pregnant at 8 vs. 28% pregnant at 4 ng/mL P(4)). Serum concentrations of E(2) at 56 h after PGF(2α) of Ovsynch were a positive predictor of pregnancy at 39 d after timed AI. In summary, cloprostenol sodium tended to improve P/AI. Cows with greater serum concentrations of P(4) at time of PGF(2α) of Ovsynch had a greater chance of luteolysis and pregnancy.

Topics: Animals; Cattle; Cloprostenol; Dinoprost; Estrus Synchronization; Female; Insemination, Artificial; Lactation; Luteolysis; Luteolytic Agents; Pregnancy; Pregnancy Rate; Progesterone; Time Factors; Treatment Outcome

To assess the efficacy and safety of 2 protocols using bromocriptine mesylate and prostaglandins to terminate unwanted pregnancy in bitches.. Prospective randomized single-blind controlled study.. 34 crossbred and purebred bitches referred for possible pregnancy termination. Seven additional pregnant bitches were used as controls.. Pregnancy was assessed by ultrasonographic examination from day 25 after mating in all bitches. Of the 34 bitches, 25 were pregnant and were randomly allocated to a treatment group. Group-1 dogs (n = 12) received a combination of increasing amounts of bromocriptine mesylate (15 to 30 microg/kg [6.8 to 13.6 microg/lb], p.o., q 12 h) and dinoprost tromethamine (0.1 to 0.2 mg/kg [0.045 to 0.09 mg/lb], s.c., q 24 h). Group-2 dogs (n =13) received a combination of increasing amounts of bromocriptine mesylate (the same schedule as group-1 dogs) and cloprostenol sodium (1 microg/kg [0.45 microg/lb], s.c., q 48 h). Both groups were treated until pregnancy termination. Results-Treatment success was 100% in both groups. Days of treatment required for pregnancy termination did not significantly differ between groups (5.0 +/- 0.6 vs 3.7 +/- 0.6 days, group-1 and group-2 dogs, respectively) although adverse effects only developed in group-1 dogs. At the end of the protocols, pseudopregnancy was observed in 3 of 12 and 6 of 13 group-1 and group-2 dogs, respectively. Pregnancy termination was followed by a mucoid sanguineous vulvar discharge for 3 to 10 days.. Results of this study indicate that protocols that combine the use of bromocriptine mesylate and prostaglandins for the termination of unwanted pregnancy in bitches are efficient and safe. The use of bromocriptine mesylate and cloprostenol had the best results and could be easily used on an outpatient basis.

Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Veterinary; Animals; Bromocriptine; Cloprostenol; Dinoprost; Dogs; Female; Pregnancy; Prospective Studies; Prostaglandins; Safety; Single-Blind Method; Treatment Outcome

To compare the effects of PGF2α (dinoprost tromethamine) and D-cloprostenol in a two-dose protocol for estrus synchronization in hair sheep during breeding season in Yucatán, México, two experiments were conducted. In experiment 1, 61 cyclic hair sheep were divided into two groups: G1 (control n = 30), two doses of 50 μg of dinoprost tromethamine IM with 12 days between applications, and G2 (n = 31), two doses of 50 μg of D-cloprostenol IM at the same time interval. For determination of progesterone levels, 16 ewes from each group were randomly selected. In experiment 2, 70 cyclic hair sheep were assigned at the same treatments (G1 and G2, n = 35) and 48 h after the second application, the ewes in estrus were detected by two vasectomized rams. Sheep with detected estrus were inseminated, and 45 days after, pregnant animals were identified by ultrasonography. An exact Fisher's test was performed for the analysis of ewes in estrus (experiments 1 and 2) and number of pregnant ewes (experiment 2); for the comparison of time between end of treatment-estrus presentation, a survival analysis was used. Duration of estrus in hours was analyzed using a generalized mixed model (GLM) ANOVA whereas plasma progesterone concentrations were analyzed by non-linear regression. There were significant differences (P < 0.05) in the proportion of ewes in estrus upon treatments (G1, 57% vs G2, 87% and G1, 37.1% vs G2, 65.7% in experiments 1 and 2, respectively), and between the end of treatment-onset estrus interval (P < 0.01), survival curves showed the highest number of sheep in estrus between 40 and 48 h (G1, 43.7 + 8.05 h vs G2, 42.9 + 6.7 h, experiment 1). There were no significant differences (P > 0.05) in duration of estrus (G1, 42 + 6.1 h, vs G2, 41.1 + 11.2 h, experiment 1) and pregnancy in the ewes that presented estrus, and were inseminated (G1, 38.4% vs 52.1%, experiment 2). With regard to concentrations of progesterone, significant differences (P < 0.01) were found between treatments, and progesterone levels before the second application of D-cloprostenol were higher. In consideration of the results, it can be concluded that in a two-dose protocol of a luteolytic agent, more ewes presented estrus in response to D-cloprostenol compared to dinoprost tromethamine with similar pregnancy rates.

Topics: Animals; Breeding; Cloprostenol; Dinoprost; Estrus; Estrus Detection; Estrus Synchronization; Female; Luteolysis; Luteolytic Agents; Male; Mexico; Pregnancy; Pregnancy Rate; Progesterone; Seasons; Sheep; Swine; Time Factors

Natural lambing in sheep in Ethiopia occurs throughout the year in a scattered manner negatively affecting survival and growth rates of the lambs born during the unfavorable season of the year. Thus, controlling the time of mating artificially using exogenous source of hormones is considered as one of the ways to mitigated problems related to haphazard lambing. To this end, an experiment was conducted to evaluate efficacy of prostaglandin-based estrus synchronization protocol in local and crossbred ewes. A total of 160 ewes (80 local and 80 crossbreds) which lambed at least once and aged 3-5 years were used. Lutalyse® (dinoprost tromethamine sterile solution equivalent to 5 mg dinoprost per ml) and its analog, Synchromate® (cloprostenol sodium equivalent to 0.250 mg cloprostenol per ml), were tested at different doses. The treatments used were intramuscular injection of (1) 2.50 ml of Lutalyse® (12.5 mg dinoprost tromethamine), (2) 2 ml of Lutalyse® (10.0 mg dinoprost tromethamine), (3) 1 ml of Synchromate® (0.25 mg of cloprostenol Sodium), and (4) 0.8 ml of Synchromate® (0.20 mg of cloprostenol Sodium). Forty ewes (20 local and 20 crossbreds) were allocated per treatment. Following injection of the respective hormones, rams of known fertility were introduced into the flock for the duration of 96 h at the ratio of one ram to 10 ewes. All estrus synchronization protocols except treatment 4 (0.8 ml of Synchromate®) induced estrus (heat) in majority (55-65%) of local and crossbred ewes within 96 h post-hormone injection. The time interval from hormone administration to onset of estrus was also more or less similar for all treatment groups except for treatment group 4 which showed heat quicker. The highest lambing rate was recorded in local ewes (84.62% (11/13) treated with 2.5 ml of Lutalyse®, whereas the least was obtained in crossbreds (33.33% (3/9) treated with 0.8 ml Synchromate®. In conclusion, even though 2.5 ml and 2 ml of Lutalyse® or 1 ml of Synchromate® were able to induce heat in majority of local and crossbred ewes, the highest lambing percentage was obtained from ewes treated with 2.5 ml of Lutalyse®. Therefore, the use of 2.5 ml Lutalyse® is recommended to synchronize estrus in local and crossbred ewes under Ethiopian smallholder sheep production system for the benefit of improved lambing rate.

Topics: Animals; Cloprostenol; Dinoprost; Drug Administration Schedule; Estrus; Estrus Synchronization; Female; Fertility; Male; Pregnancy; Seasons; Sheep

Twenty-four to 36 hours after farrowing, 192 sows were treated with a single intramuscular injection (2 ml per animal) of a prostaglandin analogue; 102 were treated with cloprostenol racemate and 97 with dinoprost tromethamine, and 90 were left untreated. There were no statistically significant differences between the groups in the percentages of sows that came into oestrus by eight days after weaning or conceived by eight days after weaning. Significantly more piglets were born per litter (10.71 and 11.00 piglets in the cloprostenol and dinoprost groups, respectively) and born alive (10.22 and 10.41, respectively) than in the controls (9.24 piglets born per litter and 8.66 piglets born alive).

Topics: Analysis of Variance; Animals; Cloprostenol; Dinoprost; Female; Fertility; Litter Size; Luteolytic Agents; Oxytocics; Postpartum Period; Pregnancy; Pregnancy Outcome; Prostaglandins, Synthetic; Reproduction; Spain; Swine

This study compared the efficacy of two sources of PGF2alpha on the reproductive performance of virgin beef heifers, after synchronization of estrus using melengestrol acetate (MGA) and PGF2alpha. Angus-based heifers (n = 1002) in five herds were fed 0.5 mg per head per day of MGA for 14 days. Nineteen days after the last day of MGA feeding, heifers were randomly assigned to receive (i.m.) either 0.5 mg cloprostenol (n = 504; Estrumate, E) or 25 mg dinoprost tromethamine (n = 498; Lutalyse, L) as a source of exogenous PGF2alpha. Heifers were observed twice daily for 5 days for signs of estrus and artificially inseminated 8-12 h later, except in herd A, wherein animals not detected in estrus by 80 h after PGF2alpha were mass-mated and no longer monitored for signs of estrus. Estrumate and Lutalyse were equally (P > 0.1) effective among all response variables evaluated, including estrus response (E, 89% and L, 86%), conception rate (E, 67% and L, 67%), and synchronized pregnancy rate (E, 61% and L, 57%). Synchrony of estrus was not affected (P > 0.1) by PGF2alpha source, and peak estrus response occurred 60 h post-PGF for both treatments. Conception rate to timed insemination was not different (P > 0.1) among Estrumate- and Lutalyse-treated heifers within herd A (14%, 4/28 and 7%, 2/29, respectively). Herd had a significant (P < 0.05) effect on all indicators of reproductive performance. Conception rates within herds A and D were influenced by technician (P < 0.05), however, this effect was balanced across treatments and no treatment by technician interaction was detected. In conclusion, when administered 19 days after a 14-day MGA feeding period, cloprostenol and dinoprost tromethamine are equally efficacious for synchronous induction of a fertile estrus in virgin beef heifers.

Topics: Animals; Cattle; Cloprostenol; Dinoprost; Estrus Synchronization; Female; Insemination, Artificial; Melengestrol Acetate; Pregnancy; Progesterone Congeners

To determine whether administration of a microdose of prostaglandin at the BAI HUI acupuncture point offers any advantage over IM injections for luteolysis, ovulatory interval, or systemic response in mares.. 17 mature cycling mares, 3 to 20 years of age and weighing 400 to 500 kg.. Conventional and microdoses of the prostaglandin dinoprost tromethamine (PGF2alpha), the analogue cloprostenol, or sterile water (control) were administered to mares in 7 treatment groups. Treatments were assigned by dose, administration site (semimembranosus, semitendinosus, or lumbosacral region), and treatment type (PGF2alpha, analogue, or sterile water). Mares were observed for ovulatory interval and systemic response to treatment, including heart, and respiratory rates, rectal temperature, and sweat score. Plasma progesterone concentrations were also determined at the time of treatment and at 24-hour intervals for 96 hours following treatment.. Ovulatory interval was shortened and progesterone concentrations decreased in prostaglandin-treated mares, compared with control mares, regardless of dose or treatment site. However, no differences in ovulatory interval were observed among prostaglandin-treated mares. Mares treated with conventional doses of PGF2alpha had greater systemic responses than mares treated with microdoses of PGF2alpha or sterile water.. Administration of prostaglandins at the BAI HUI acupuncture point does not appear to offer any advantage over administration at standard IM injection sites for induction of luteolysis or to shorten the ovulatory interval. However, administration of a microdose of the analogue cloprostenol was effective at inducing luteolysis and shortening ovulatory interval regardless of administration site.

Topics: Abortifacient Agents, Nonsteroidal; Acupuncture; Animals; Body Temperature; Cloprostenol; Corpus Luteum; Dinoprost; Female; Heart Rate; Horses; Injections, Intramuscular; Lumbosacral Region; Luteolytic Agents; Ovulation; Progesterone; Random Allocation; Respiration; Sweat

Gilts were treated during midgestation with prostaglandin (PG) F to study the efficacy of different treatment regimens on induction of abortion and to determine the adverse consequences of PGF-induced abortion in swine. In study 1, pregnant purebred Duroc gilts (60 to 90 days of gestation) were given (IM) 500 micrograms of cloprostenol (n = 12), 20 mg of dinoprost tromethamine (n = 11), or 10 mg of dinoprost tromethamine repeated 12 hours later by an additional 10 mg of dinoprost tromethamine (n = 11). The percentage of gilts that aborted and percentage of aborted gilts that returned to estrus for each treatment group were as follows: cloprostenol, 91.7% and 100%, respectively; 20 mg of dinoprost tromethamine, 36.4% and 25.0%, respectively; and 10 + 10 mg of dinoprost tromethamine, 100% and 90.9%, respectively. Treatment with cloprostenol and with 10 + 10 mg of dinoprost tromethamine caused more gilts to abort (P less than 0.01) than did treatment with 20 mg of dinoprost tromethamine. Gilts that did not abort were given a second treatment with 10 + 10 mg of dinoprost tromethamine. When the abortions by gilts initially treated with 500 micrograms of cloprostenol or 10 + 10 mg of dinoprost tromethamine were combined with those re-treated with 10 + 10 mg of dinoprost tromethamine, 32 of 33 (97.0%) gilts aborted, and 30 of the 32 (93.8%) aborted gilts returned to estrus.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Abortion, Veterinary; Animals; Cloprostenol; Dinoprost; Estradiol; Estrus; Female; Luteinizing Hormone; Pregnancy; Pregnancy, Animal; Progesterone; Prostaglandins F, Synthetic; Swine; Swine Diseases